Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

14d ago, source:

Research and development expenses were approximately $40.8 million and $38.6 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily due to increases in ...

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

7d ago, source: Zacks.com on MSN

A downtrend has been apparent in Cue Biopharma, Inc. (CUE) lately. While the stock has lost 5.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Cue Biopharma Inc (CUE) Shares Down Despite Recent Market Volatility

12d ago, source: newsheater

To wrap up, the performance of Cue Biopharma Inc (CUE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock ...

Q4 2023 Cue Biopharma Inc Earnings Call

14d ago, source: Yahoo Finance

Stephen Willey; Analyst; Stifel Financial Corp. Reni Benjamin; Analyst; JMP Securities LLC Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. (Operator Instructions) As a ...

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

13d ago, source:

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.0, a high estimate of $10.00, ...

Cue Biopharma to Host Business Update Call and Webcast

21d ago, source: Business Insider

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate ...

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

14d ago, source: Seeking Alpha

Greetings and welcome to the Cue Biopharma Investor Update call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the presentation. [Operator ...

Cue Biopharma Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

14d ago, source: Morningstar

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate ...

Q4 2023 Cue Biopharma Inc Earnings Call

14d ago, source: Yahoo Finance

Stephen Willey; Analyst; Stifel Financial Corp. Reni Benjamin; Analyst; JMP Securities LLC Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. (Operator Instructions ...